CytoDyn (CYDY) Stock Price, News & Analysis

Company Overview

CytoDyn Inc. is a clinical-stage biotechnology company focused on the development and commercialization of novel immunotherapies. The company’s lead product candidate, leronlimab (PRO 140), is a humanized monoclonal antibody designed to block the CCR5 receptor, which plays a critical role in HIV infection and certain cancer pathways. CytoDyn is advancing leronlimab through multiple clinical trials targeting indications such as treatment-resistant HIV, metastatic triple-negative breast cancer, and other oncology and inflammatory conditions.

In its pursuit of regulatory approvals, CytoDyn has conducted Phase II and Phase III studies of leronlimab in people living with HIV who have experienced virologic failure on existing therapies. The company has also initiated trials exploring leronlimab’s potential to modulate immune response in critically ill COVID-19 patients, capitalizing on the antibody’s mechanism of action to reduce inflammatory damage. CytoDyn’s research programs extend to combination therapies as well as collaborations with academic institutions and research centers.

Headquartered in Vancouver, Washington, CytoDyn maintains its research and development operations in the United States while engaging contract research organizations and clinical sites in North America, Europe, and other regions. The company works to build strategic partnerships to support global clinical development and regulatory submissions. CytoDyn holds certain licensing agreements for leronlimab and continues to explore additional collaborations to expand the antibody’s commercial reach.

Leadership at CytoDyn includes Nader Pourhassan, who serves as President and Chief Executive Officer, guiding the company through its clinical milestones and regulatory interactions. Since its founding, CytoDyn has emphasized a science-driven approach to address unmet medical needs in infectious diseases and oncology. The company remains committed to advancing its pipeline toward potential approvals and eventual commercialization.

Key Stats

• Today's Range: $0.34 to $0.37
• 50-Day Range: $0.23 to $0.37
• 52-Week Range: $0.21 to $0.40
• Volume: 2.42 million shs
• Average Volume: 2.27 million shs
• Market Capitalization: $483.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CytoDyn Stock Analysis - MarketRank™

CytoDyn scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for CytoDyn.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of CytoDyn is -11.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CytoDyn is -11.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.72% of the float of CytoDyn has been sold short.

Short Interest Ratio / Days to Cover

CytoDyn has a short interest ratio ("days to cover") of 6.19.

Change versus previous month

Short interest in CytoDyn has recently increased by 0.76%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CytoDyn does not currently pay a dividend.

Dividend Growth

CytoDyn does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for CytoDyn this week, compared to 0 articles on an average week.

Search Interest

Only 4 people have searched for CYDY on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added CytoDyn to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CytoDyn insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.00% of the stock of CytoDyn is held by insiders.

Percentage Held by Institutions

5.06% of the stock of CytoDyn is held by institutions.

Company Calendar

• Last Earnings: 1/09/2026
• Today: 5/19/2026
• Fiscal Year End: 5/31/2026
• Next Earnings (Estimated): 7/29/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:CYDY
• Previous Symbol: NASDAQ:CYDY
• CIK: 1175680
• Web: www.cytodyn.com
• Phone: (360) 980-8524
• Fax: N/A
• Employees: 20
• Year Founded: 2002

Profitability

• EPS (Trailing Twelve Months): ($0.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $3.74 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -182.93%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.37
• Quick Ratio: 0.37

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.08) per share
• Price / Book: -4.41

Miscellaneous

• Outstanding Shares: 1,369,730,000
• Free Float: 1,356,037,000
• Market Cap: $483.10 million
• Optionable: Not Optionable
• Beta: 1.15